Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma
NCT: NCT05028725 · RECRUITING
Brief Summary
In the current protocol, we propose a study to evaluate a novel, combined esophageal sponge-methylation biomarker strategy for the early detection of esophageal squamous cell carcinoma (ESCC) as well as its precursor, esophageal squamous dysplasia (ESD). This strategy leverages the 'EsophaCap', a swallowable, retrievable sponge, with subsequent evaluation of the sample using a novel molecular biomarker assay. This biomarker assay evaluates methylation levels in select genes, which have been shown to differ significantly between ESCC cases and controls in pilot studies. Detection of methylation markers highly associated with ESCC could help identify patients with concurrent ESCC or at high risk of imminently developing this condition. If successful, this strategy could result in a paradigm shift for esophageal cancer control strategies in Tanzania and other high-incidence ESCC regions.
Frequently Asked Questions
What is Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma?
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma is a clinical trial registered under NCT05028725. Current status: RECRUITING.
What is the status of NCT05028725?
The current status of NCT05028725 (Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma) is: RECRUITING.
When did Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma start?
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma started on 2022-05-16.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.